Epperly Melissa B, Roivant Sciences Ltd. (ROIV) insider trading activity

Epperly Melissa B, is of Roivant Sciences Ltd.. Currently has a direct ownership of 56,904 shares of ROIV, which is worth approximately $1.15 Million. The most recent transaction as insider was on Oct 20, 2025, when has been sold 1,056 shares (Common Shares) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 56.9K

1.89% 3M change

49.6% 12M change

Total Value Held $1.15 Million

Epperly Melissa B, Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 20 2025	BUY Grant, award, or other acquisition	-	1,056 Added 1.82%	56,904 Common Shares
Sep 10 2025	SELL Other acquisition or disposition	$22,871 $13.77 p/Share	1,661 Reduced 2.89%	55,848 Common Shares
Sep 10 2025	BUY Grant, award, or other acquisition	-	14,524 Added 20.16%	57,509 Common Shares
Jul 17 2025	BUY Grant, award, or other acquisition	-	1,609 Added 3.61%	42,985 Common Shares
Apr 17 2025	BUY Grant, award, or other acquisition	-	1,847 Added 4.27%	41,376 Common Shares
Jan 23 2025	SELL Payment of exercise price or tax liability	$2,017 $11.21 p/Share	180 Reduced 0.45%	39,529 Common Shares
Jan 23 2025	BUY Grant, award, or other acquisition	-	1,672 Added 4.04%	39,709 Common Shares

Oct 21 2024	BUY Grant, award, or other acquisition	-	1,613 Added 4.07%	38,037 Common Shares
Sep 12 2024	SELL Other acquisition or disposition	$51,449 $12.12 p/Share	4,245 Reduced 10.44%	36,424 Common Shares
Sep 10 2024	BUY Grant, award, or other acquisition	-	16,406 Added 28.74%	40,669 Common Shares
Jul 23 2024	BUY Grant, award, or other acquisition	-	1,702 Added 6.55%	24,263 Common Shares
Apr 24 2024	SELL Payment of exercise price or tax liability	$1,340 $10.9 p/Share	123 Reduced 0.54%	22,561 Common Shares
Apr 24 2024	BUY Grant, award, or other acquisition	-	1,146 Added 4.81%	22,684 Common Shares
Jan 19 2024	BUY Grant, award, or other acquisition	-	1,207 Added 5.31%	21,538 Common Shares
Oct 16 2023	BUY Grant, award, or other acquisition	-	1,226 Added 5.69%	20,331 Common Shares
Sep 12 2023	BUY Grant, award, or other acquisition	-	17,825 Added 48.27%	19,105 Common Shares
Jul 03 2023	BUY Grant, award, or other acquisition	-	1,280 Added 50.0%	1,280 Common Shares

Also insider at

ZNTL

Zentalis Pharmaceuticals, Inc. Healthcare

Chief Financial Officer

KNTE

Kinnate Biopharma Inc. Healthcare

NAUT

Nautilus Biotechnology, Inc. Healthcare

Director

EMB